These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1182 related items for PubMed ID: 15698420

  • 1. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications.
    Wolf G, Ritz E.
    Kidney Int; 2005 Mar; 67(3):799-812. PubMed ID: 15698420
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D.
    Presse Med; 2002 Nov 09; 31(36):1714-20. PubMed ID: 12467154
    [Abstract] [Full Text] [Related]

  • 4. [The renin-angiotensin-aldosterone system -- more complex as previously thought].
    Wolf G.
    Med Klin (Munich); 2005 Aug 15; 100(8):471-7. PubMed ID: 16096728
    [Abstract] [Full Text] [Related]

  • 5. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
    Schindler C.
    Ther Adv Cardiovasc Dis; 2008 Aug 15; 2(4):233-48. PubMed ID: 19124424
    [Abstract] [Full Text] [Related]

  • 6. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan 15; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 7. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R.
    Kidney Int; 2001 Jun 15; 59(6):2282-9. PubMed ID: 11380832
    [Abstract] [Full Text] [Related]

  • 8. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).
    Luno J, Praga M, de Vinuesa SG.
    Curr Pharm Des; 2005 Jun 15; 11(10):1291-300. PubMed ID: 15853685
    [Abstract] [Full Text] [Related]

  • 9. Recent changes in the landscape of combination RAS blockade.
    Epstein BJ, Smith SM, Choksi R.
    Expert Rev Cardiovasc Ther; 2009 Nov 15; 7(11):1373-84. PubMed ID: 19900020
    [Abstract] [Full Text] [Related]

  • 10. The Remission Clinic approach to halt the progression of kidney disease.
    Remission Clinic Task Force, Clinical Research Center "Aldo e Cele Daccò".
    J Nephrol; 2011 Nov 15; 24(3):274-81. PubMed ID: 21534237
    [Abstract] [Full Text] [Related]

  • 11. [Blockade of the renin-angiotensin system by a combination of ACE inhibitors and AT1 receptor antagonists].
    Azizi M.
    Rev Prat; 2004 Jun 15; 54(11):1167-74. PubMed ID: 15496022
    [Abstract] [Full Text] [Related]

  • 12. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L, Kocks MJ, Laverman GD, Navis G.
    Minerva Med; 2004 Oct 15; 95(5):395-409. PubMed ID: 15467515
    [Abstract] [Full Text] [Related]

  • 13. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.
    Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J.
    J Am Soc Nephrol; 2006 Dec 15; 17(12 Suppl 3):S250-4. PubMed ID: 17130270
    [Abstract] [Full Text] [Related]

  • 14. Direct renin inhibition in a rat model of chronic allograft injury.
    Rusai K, Schmaderer C, Hermans JJ, Lutz J, Heemann U, Baumann M.
    Transplantation; 2011 Nov 15; 92(9):999-1004. PubMed ID: 21956196
    [Abstract] [Full Text] [Related]

  • 15. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 15; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 16. Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
    Segura J, Praga M, Campo C, Rodicio JL, Ruilope LM.
    J Renin Angiotensin Aldosterone Syst; 2003 Mar 15; 4(1):43-7. PubMed ID: 12692753
    [Abstract] [Full Text] [Related]

  • 17. Impact of angiotensin II on the kidney: does an angiotensin II receptor blocker make sense?
    Hollenberg NK.
    Am J Kidney Dis; 2000 Sep 15; 36(3 Suppl 1):S18-23. PubMed ID: 10986155
    [Abstract] [Full Text] [Related]

  • 18. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists.
    Taal MW, Brenner BM.
    Kidney Int; 2000 May 15; 57(5):1803-17. PubMed ID: 10792600
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct 15; 14(79):180-6. PubMed ID: 16285075
    [Abstract] [Full Text] [Related]

  • 20. [Angiotensin II receptor blockers: current status and future prospects].
    Corvol P, Plouin PF.
    Drugs; 2002 Oct 15; 62 Spec No 1():53-64. PubMed ID: 12036389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 60.